Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Rhea-AI Summary

Telix Pharmaceuticals (ASX/NASDAQ: TLX) announces its significant presence at the SNMMI 2025 Annual Meeting in New Orleans, featuring five abstract presentations and two satellite symposia. Key highlights include presentations on the ProstACT Global Phase 3 study of TLX591 for advanced prostate cancer, preclinical data on TLX252 alpha therapy for CAIX-expressing tumors, and clinical study data on Illuccix's impact on decision-making. The company will showcase its extensive theranostic portfolio at booth #408, covering various oncology areas including urologic, neuro-oncology, musculoskeletal, and hematologic cancers. Two sponsored symposia will focus on CAIX-PET imaging in renal cancer and Illuccix PSMA-PET imaging in prostate cancer, featuring presentations from leading medical experts.

Insights

Biotech Investment Analyst

Telix's strong SNMMI presence highlights Phase 3 ProstACT Global study and pipeline advancement, reinforcing its theranostic leadership position.

Telix's significant presence at the SNMMI 2025 Annual Meeting with five abstract presentations and two satellite symposia demonstrates the company's expanding clinical footprint in precision nuclear medicine. The featured Phase 3 ProstACT Global study of TLX591 represents their most advanced therapeutic candidate for prostate cancer, a critical value driver approaching late-stage clinical validation. This pivotal trial (NCT06520345) could potentially position Telix to enter the lucrative radioligand therapy market, competing with established players.

The preclinical data on TLX252 alpha therapy candidate in CAIX-expressing tumors combined with DNA damage response inhibitors (DDRIs) highlights Telix's strategic focus on combination approaches, which typically show enhanced efficacy versus monotherapies. This early-stage program targeting carbonic anhydrase IX (CAIX) extends their reach beyond prostate cancer into renal cell carcinoma, demonstrating pipeline diversification.

The clinical presentations on Illuccix® PSMA-PET imaging impact on clinical decision-making underscores Telix's ability to leverage its commercial diagnostic product while advancing complementary therapeutics—the core of the theranostic approach. Their new PSMA biopsy trial further strengthens Illuccix's clinical utility and potential market expansion.

Telix's comprehensive exhibition presence across multiple cancer types (urologic, neuro-oncology, musculoskeletal, hematologic) and pan-cancer programs reveals a strategically diversified pipeline with multiple shots on goal, reducing clinical development risk. The key opinion leader engagement through sponsored symposia strengthens their scientific credibility and builds awareness among the precise medical specialists who influence adoption of nuclear medicine technologies.

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.

Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix’s TLX252 alpha therapy candidate in CAIX¹ -expressing tumors in combination with DDRIs², and clinical study data on Illuccix® impact on decision-making.

Two sponsored symposia will highlight innovation in precision diagnostics, the first on CAIX-PET³ imaging in renal cancer, and the second on Illuccix PSMA-PET⁴ imaging in prostate cancer, including Telix’s new PSMA biopsy trial.

Dr. David N. Cade, Group Chief Medical Officer, Telix, said, “Telix’s broad representation at this year’s SNMMI Annual Meeting highlights the strength of our innovative pipeline and commercial programs. Our sponsored symposia, featuring leading key opinion leaders, further reflect our commitment to expanding clinical utility and advancing cancer care so that more patients may benefit from precision theranostics.”

Visit booth #408 to discuss Telix’s extensive theranostic portfolio in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), hematologic oncology, its investigational pan-cancer programs, medical technologies, and opportunities for collaboration.

Presentation details are listed below (all times CDT): 

Title: Impact of ⁶⁸Ga-PSMA-11 PET/CT on clinical management of prostate cancer patients in different clinical settings
Presenter: Alirez Ghodsi, University of Washington, Seattle, WA

1. Date and Time: Sunday, June 22 | 5:00 PM – 5:30 PM
   Location: Hall B-C
   Format: Oral
   Session: POP03 Oncology: Clinical Diagnosis & Therapy POPs
2. Date and Time: Sunday, June 22 | 5:30 PM – 6:15 PM
   Location: Hall B-C | Science Pavilion
   Format: Poster
   Session: MTA03 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, Part 1
   

Title: A multinational, multicenter, prospective, randomized, controlled, open-label, Phase 3 study of ¹⁷⁷Lu-rosopatamab tetraxetan (TLX591) in combination with standard of care versus standard of care alone in patients with PSMA-expressing prostate cancer (ProstACT Global)
Presenter: Oliver Sartor, LCMC Hospitals, New Orleans, LA
Date and Time: Monday, June 23 | 12:30 PM – 1:15 PM
Location: Hall B-C | Science Pavilion
Format: Poster
Session: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, Part 2
ClinicalTrials.gov ID: NCT06520345

Title: Enhanced antitumor efficacy of DNA damage response inhibitors combined with ²²⁵Ac-DOTA-girentuximab (TLX252)
Presenter: Andrew Scott AM, Austin Health, Melbourne, Australia
Date and Time: Tuesday, June 24 | 10:10 AM – 10:20 AM
Location: 223 (Convention Center)
Format: Oral
Session: SS29 Radiopharmaceutical Developments – Preclinical and Early Phase

Title: A prospective intra-individual comparison of ⁶⁸Ga-PSMA-11 PET/CT and ^99mTc-PSMA-GCK01/RHN001DX SPECT/CT to identify a suitable imaging surrogate for phenotyping prior to PSMA-RLT
Presenter: Honest Ndlovu, Nuclear Medicine Research infrastructure (NuMeRI), Pretoria, South Africa
Date and Time: Tuesday, June 24 | 10:20 AM – 10:30 AM
Location: 223 (Convention Center)
Format: Oral
Session: SS29 Radiopharmaceutical Developments – Preclinical and Early Phase

Satellite Symposia:

Title: Illuminating renal cancer: CAIX-PET imaging and the shift toward precision diagnostics
Speakers:

• Shadi Esfahani, MD, Assistant Professor of Radiology, Massachusetts General Hospital, MA
• Timothy McClure, MD, Assistant Professor of Urology and Radiology, Weill Cornell Medicine, NY

Date and Time: Monday, June 23 | 6:45 – 7:45 AM
Location: R02-R03, Level 2 (Convention Center)

Title: Enhancing cancer care with precision radiopharmaceuticals: Innovation in prostate cancer
Moderator: Munir Ghesani, MD Chief Medical Officer, United Theranostics
Speakers:

• Bital Savir-Baruch, MD, Chief of Nuclear Medicine and Theranostics, Professor of Medical Imaging, University of Arizona, AZ
• Mary Jessel, Senior Vice President, Global Medical Affairs, Telix Pharmaceuticals
• Scott Tagawa, MD, Professor of Medicine & Urology, Weill Cornell Medicine, NY
  

Date and Time: Monday, June 23 | 5:30 - 6:30 PM
Location: R04-R05, Level 2 (Convention Center)

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple countries globally. TLX591, TLX252 and RHN001Dx have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Telix Media Relations (U.S.)

Eliza Schleifstein
ES Media Relations
Email: eliza@schleifsteinpr.com   
Phone: 917-763-8106

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

---

¹ Carbonic anhydrase IX.
² DNA damage response inhibitors.
³ Imaging of carbonic anhydrase IX with positron emission tomography.
⁴ Imaging of prostate-specific membrane antigen with positron emission tomography.

FAQ

What will Telix Pharmaceuticals present at SNMMI 2025?

Telix will present five abstract presentations and two satellite symposia, featuring their developmental theranostic programs and commercial products, including the ProstACT Global Phase 3 study and preclinical data on TLX252 alpha therapy.

When and where is the SNMMI 2025 Annual Meeting taking place?

The SNMMI 2025 Annual Meeting is being held in New Orleans, Louisiana from June 21-24, 2025.

What are the main topics of Telix's satellite symposia at SNMMI 2025?

The two satellite symposia focus on CAIX-PET imaging in renal cancer and Illuccix PSMA-PET imaging in prostate cancer, featuring presentations from leading medical experts.

What therapeutic areas does Telix's theranostic portfolio cover?

Telix's theranostic portfolio covers urologic oncology (prostate, kidney, bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), hematologic oncology, and investigational pan-cancer programs.